Article thumbnail

Cucurbitacin-I (JSI-124) activates the JNK/c-Jun signaling pathway independent of apoptosis and cell cycle arrest in B Leukemic Cells

By Ganchimeg Ishdorj, James B Johnston and Spencer B Gibson
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3146936
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2006). Activation of hypoxia-inducible factor-1alpha is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression. Clinical Cancer Research
  2. (2002). Angiogenesis and the unique nature of tumor matrix. Molecular Biotechnology
  3. (2001). Angiogenesis in B-cell chronic lymphocytic leukemia: methods of study, clinical significance and prognostic implications. Leukemia and Lymphoma
  4. (2004). Boucher DM: Functions of MAP Kinases: Insights from GeneTargeting Studies.
  5. (2003). Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Molecular Cancer Therapeutics
  6. (2002). DF: B-CLL cells are capable of synthesis and secretion of both pro-and anti-angiogenic molecules. Leukemia
  7. (2009). Genetic and pharmacological inhibition of JNK ameliorates hypoxia-induced retinopathy through interference with VEGF expression.
  8. (2006). Goppelt-Struebe M: STAT3-independent inhibition of lysophosphatidic acid-mediated upregulation of connective tissue growth factor (CTGF) by cucurbitacin I. Biochemical Pharmacology
  9. (2008). Hicklin DJ: VEGF-targeted therapy: mechanisms of anti-tumour activity. Nature Reviews Cancer
  10. (2000). Holash SJ: Vascularspecific growth factors and blood vessel formation. Nature
  11. (2002). Hotamisligil GS: A central role for JNK in obesity and insulin resistance. Nature
  12. (2002). Inhibition of NFkappaB activity decreases the VEGF mRNA expression in MDA-MB-231 breast cancer cells. Breast Cancer Research and Treatment
  13. inhibits glioblastoma multiforme cell proliferation through G(2)/M cell cycle arrest and apoptosis augment. Cancer Biology and Therapy
  14. (2006). JNK regulation of oncogenesis. Molecular Cells
  15. (2009). Kuo ML: Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/ JNK/AP-1 pathway. Carcinogenesis
  16. (2001). Mammalian MAP kinase signalling cascades. Nature
  17. (2003). Map kinase signaling pathways Map kinase signaling pathways and hematologic malignancies. Blood
  18. (2000). MAP kinases and hypoxia in the control of VEGF expression. Cancer and Metastasis Reviews
  19. (2006). Mechanistic investigation and implications of photodynamic therapy induction of vascular endothelial growth factor in prostate cancer. Cancer Research
  20. (2005). NE: VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance. Leukemia
  21. (2006). Ødum N: Jak3-and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma.
  22. (2006). Ødum N: Jak3-and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia
  23. (1999). Rat embryo fibroblasts transformed by c-Jun display highly metastatic and angiogenic activities in vivo and deregulate gene expression of both angiogenic and antiangiogenic factors. Cell Growth and Differentiation
  24. (2000). RK: Angiogenesis in cancer and other diseases. Nature
  25. (2010). SB: Inhibition of constitutive activation of STAT3 by curcurbitacin-I (JSI-124) sensitized human B-leukemia cells to apoptosis. Molecular Cancer Therapeutics
  26. (2008). SB: Lysophosphatidic acid (LPA) induces the expression of VEGF leading to protection against apoptosis in B-cell derived malignancies. Cell Signaling
  27. (2008). SB: Lysophosphatidic acid protects cancer cells from histone deacetylase (HDAC) inhibitor-induced apoptosis through activation of HDAC.
  28. (2009). SB: Lysophosphatidic acid receptor expression in chronic lymphocytic leukemia leads to cell survival mediated though vascular endothelial growth factor expression. Leukemia and Lymphoma
  29. (2003). Sebti SM: Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Research
  30. (1999). Serine phosphorylation and negative regulation of
  31. (2000). Signal transduction by the JNK group of MAP kinases. Cell
  32. (2000). STAT signaling in the pathogenesis and treatment of leukemias. Oncogene
  33. (1997). STAT3 serine phosphorylation by ERK-dependent and-independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol
  34. (1998). Stress-activated kinases regulate protein stability. Oncogene
  35. (2005). SX: Cucurbitacins and cucurbitane glycosides: structures and biological activities. Natural Product Reports
  36. (2008). Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model. Immunology and Cell Biology
  37. (2010). Thoennissen NH: Cucurbitacin: ancient compound shedding new light on cancer treatment. Scientific World Journal
  38. (2005). Tweardy DJ: Targeting Stat3 in cancer therapy. Anticancer Drugs
  39. (2005). Ultraviolet B irradiation of human skin induces an angiogenic switch that is mediated by upregulation of vascular endothelial growth factor and by downregulation of thrombospondin-1.
  40. (2005). VEGF-targeted therapy: therapeutic potential and recent advances. Oncologist
  41. (2011). Wong AJ: The role of the c-Jun N-terminal kinase 2-α-isoform in non-small cell lung carcinoma tumorigenesis. Oncogene